IntraOp®
Mobetron®



A NEW GENERATION OF IORT

Mobetron delivers the simplicity of electrons.



GREATER PRECISION

SHORTER TREATMENT TIME

BROADER APPLICATION

Mobetron. First. And Foremost.

IntraOp® Mobetron®, the first portable, self-shielded electron-beam linear accelerator for IORT. A new generation proven by a legacy of success.

Mobetron is the unparalleled approach to hypofractionated radiation therapy and is preferred by the leading cancer physicians and radiation oncologists in the most innovative and proven hospitals, clinics and academic centers around the world. As the first portable, self-shielded electron-beam linear accelerator, Mobetron stands as the breakthrough technology in delivering Intraoperative Radiation Therapy to cancer patients during surgery. Two decades of proven clinical data and more than 20,000 patients treated confirms Mobetron as the new standard of care in electron IORT treatment.

As elementary particles, electrons simply perform better for IORT. But don't take our word for it. The clinical data proves it. Because when it comes to electrons, simple means better.

Precise. Efficient. Cost-effective. Simply Elementary.

In the simplest terms, Mobetron is the bottom-line intraoperative solution enabling physicians to be more effective in delivering optimal treatment for a broad array of indications.

For cancer centers and clinics, “simple” translates to greater accessibility at a lower cost. This means optimized portability, adaptability, and control, all with better therapeutic benefit. Designed to maximize return on investment while reducing risk to patients, electron IORT creates a competitive clinical advantage by offering a more efficient alternative for patients seeking better treatment. For breast cancer patients, Mobetron delivers a full dose of electron IORT in only minutes, replacing weeks of adjuvant radiation therapy. For pancreatic cancer patients, Mobetron is empowering new treatment options for patients historically defined as unresectable. For a host of emerging indications, electron IORT with Mobetron may indeed represent a future in whole body cancer care.

As clinical data matures, the arguments supporting the benefits of electron IORT continue to strengthen. Mobetron is clearly winning favor among the world's best cancer centers and clinics as a vital tool in comprehensive cancer care. Why? Because we enable real-time multidisciplinary care efficiently and economically.

“The physical characteristics of the electron beam allows for better accuracy, superior reliability, and allows us to deliver the dose of radiation to targeted tissues much faster.”

VENITA WILLIAMS, MD

Radiation Oncologist, St. Joseph Hospital
Orange, California

Electron IORT:

Why Electrons?

High-energy electron particles uniformly deliver precise and reliable radiation to cancer tissue at a greater range of depths with lower exit doses. Electrons are simply more efficient.

Electron IORT Means Greater Dose Homogeneity



Chart demonstrates comparable radiation fall-off of Mobetron vs. 50 kV. Electron IORT provides greater dose homogeneity to tumor volume while eliminating any skin dose.

6 MeV:	20 mm*
9 MeV:	30 mm*
12 MeV:	40 mm*
50 kV:	3 mm*

** 80% depth dose*

The Case for Electron IORT.

Oncologists know that precision in treatment doses and volume, as well as uniform dosimetry, are vital components in the battle against cancer. With shorter treatment cycles and minimal impact to healthy tissue for multiple indications, Mobetron is simply more effective and more productive.

Mobetron is proven effective in the following indications:

- Breast Cancer
- Pancreatic Cancer
- Colorectal Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Sarcomas



GREATER PRECISION

Electron IORT delivers radiation only to involved tissue and enables a full spectrum of electron energies from 6, 9, 12 MeV for more controlled depth.

SHORTER TREATMENT TIME

Mobetron delivers a full dose of electron IORT in only two minutes during surgery, thereby replacing weeks of therapy.

BROADER APPLICATION

Proven success in multiple indications of cancer. Mobetron delivers the right dose at the right depth for the right volume.

FEWER SIDE EFFECTS

Direct dose to the tumor bed avoids healthy tissue and organs. Precise application means fewer side effects following treatment.

LOWER RECURRENCE RATE

Ablative dose of electrons targets positive surgical margins and microscopic disease to improve local control.

Mobetron. Smarter. Greater Mobility. Technically Better.

We understand that we're promising a lot and these are bold claims, indeed. But we can rely on two decades of clinical data to verify the success of electron IORT with Mobetron. And it's only getting better.

More. For less.

At the forefront of integrating radiation and surgical oncology, Mobetron delivers the right dose at the right depth for the right volume. This means providing more—to the cancer center, the physician, and the patient—in less time. But how?

It begins with some of the features from the previous pages—portability and self-shielding. Accurate and uniform dosimetry. A range of the most useful energies (6, 9, 12 MeV) offering greater adaptability in treating a broader array of applications with better therapeutic ratio than other available radiotherapy tools. We have been able to stand behind those claims for more than twenty years. And like protons or other particles, electrons are also effective particles for therapy that provide precise treatment with low exit doses. But electrons come at a fraction of the cost.

Technically advanced.

So what sets us apart from our closest competitors? Let's begin with a greater range of mobility: Six degrees of freedom offers superlative access to difficult treatment areas. Automated soft docking alignment ensures more accuracy and safety in a fraction of the time with a broader range of high density applicator sizes and geometries. Simple, single-hand positioning speeds up treatments. Our integrated beam stopper and reduced lateral stray radiation ensures safety and increases the potential workload for the operating room.

Key Mobetron Features

1. Portable design allows ease of movement within OR and throughout the facility
2. Self-propelled differential drive system enables remote-controlled mobility
3. Self shielding (less than 0.3µSv/gy @3 meters) ensures safe radiation in OR
4. Automated soft docking alignment ensures accuracy and safety in less time
5. Integrated beam stopper reduces stray radiation. Remains consistent in all treatment positions
6. Adjustable treatment depth (1-4cm d80) for precise dose delivery in prescribed volume
7. Advanced motion control (six degrees of freedom) for greatest range of mobility
8. Three energies (6, 9, 12 MeV) adjustable for various treatment conditions
9. Simple daily quality assurance system is AAPM TG72 compliant
10. Configured for compatibility with image-guided electron therapy
11. Touch screen console + ergonomic remote means intuitive, real-time control and diagnostics



12. Broad range of applicators (3-10 cm in 5 mm increments) for precise treatment



13. Large Field Applicators radiate sarcomas in a single treatment (7cm x 12cm, 8cm x 15cm, 8cm x 20cm)

A New Generation. Always Improving.

Building upon a proven legacy isn't easy. And after all this time, Mobetron has the unique distinction of being both: the standard in electron IORT *and* a center of innovation in the fight against cancer.

Now in its third generation, Mobetron builds upon the elements that underscore its efficiency and economic benefits in the OR. By now, it is clear that the precision, speed, and effectiveness of Mobetron is a competitive advantage that extends from the facility, to its physicians, and on to patients. Consider new enhancements in Mobetron's self-propelled differential drive system, integrated shielding and automatic treatment alignment and it only becomes a more effective tool.

These are just some of the ways we have responded to clinicians seeking improved performance in the operating room. We will always keep innovating.



Self-Propelled Drive System

Designed to maximize portability within the OR and throughout the facility, this new system improves accessibility with a smaller footprint than before, easing the burden of storage and increasing mobility.

- Differential steering system enables remote-controlled mobility
- Fine motor control ensures precise and safe treatment setup in the OR
- 20% smaller footprint makes storage easier, mobility less cumbersome
- Extended battery range supports >1000m travel
- Contributes to Mobetron's six degrees of freedom
- Reduces treatment time with quicker positioning

Automatic Soft Docking System

To enable the most precise alignment in the shortest amount of time is both a clinical necessity *and* a business advantage. Mobetron's new system does both by using direct visual confirmation for pre-aligning applicators and keeping them in place during the docking process.

- Proprietary alignment system with < 1mm and 0.5° accuracy
- Facilitates simultaneous movement in multiple axes
- Applicators are pre-aligned using direct visual confirmation
- Applicator position is maintained during the soft docking process
- Established sterility barrier between accelerator and patient
- LCD monitor with enhanced user interface and ergonomic controller

Improved Shielding

Advanced shielding in our third generation Mobetron **reduces lateral stray radiation by 50%** without adding weight. Combined with the integrated beam stopper, it delivers ease-of-use over remote shields. By automatically tracking the treatment head for all positions, the Mobetron beam stopper ensures maximum performance and safety.

- Most effective approach to mitigating local stray radiation
- Fully integrated beam shield vs. remote system in other devices
- Consistent shielding in beam axis from every treatment position
- Shields facilities located below treatment beam
- Later stray radiation reduced to less than 0.3uSv/Gy @ 3 meters from the beam line

Next Gen Applicators + Positioning

Using the best material for the widest range of applicators means they are less invasive, lighter weight and compatible with imaging and steam sterilization. Our pneumatic arm and other positioning solutions ensure greater confidence in setting up treatments more quickly, accurately and efficiently. Every time.

- HDRT applicators are image friendly and steam sterilizable
- Largest array of applicator geometries with over 66 available
- Large field applicators (up to 8cm x 20cm) optimized for sarcomas
- Pneumatic arm makes for easy, one-hand positioning
- Transparent boluses increase treatment precision and surface uniformity

Range of Motion: Six Degrees of Freedom

Enabling unencumbered treatment access within a busy operating room requires mobility and an expansive range of motion from every treatment angle. More so than the competition, Mobetron provides both—by way of six degrees of freedom.

The range of motion and mobility with Mobetron delivers superlative access and control in patient reach. This equates to greater treatment flexibility and quicker treatment setup times. Mobetron's extended patient reach and isocentric motion enables breast cancer treatments to be standardized for left and right breasts, maximizing work flow and OR efficiency.

Mobetron Motion:

Gantry:	**+/- 45°**
Lateral:	**+/- 5 cm**
Tilt:	**+10°/-30°**
Longitude:	**+/- 5 cm**
Vertical:	**+/- 30 cm**
Rotation:	**360°**
Patient Reach:	**76cm (nominal)** **71cm (minimum)**

Mobetron's Extended Patient Reach Provides Flexibility.



Gantry:



Lateral:

Tilt:

Longitude:



Vertical:

Rotation:



Mobetron.

"It has to be the best. That's why we chose Mobetron."

JULIE REILAND SMITH, MD, FACS

Breast Surgeon, Avera Regional Cancer Center
Sioux Falls, South Dakota

A Proven Legacy. A Promising Future.

Electron IORT is backed by professional consensus guidelines for treating an increasing number of indications. For surgical and radiation oncologists alike, Mobetron provides a unique advantage with real-time multidisciplinary care. Now, and in the future.



20,000 Patients Treated

Consensus across the board.

Supported by professional radiotherapy consensus guidelines, the Mobetron has a proven history of treatment in breast cancer, colorectal cancer, head and neck cancers, gynecological cancers as well as sarcomas. We have built our reputation on it and successfully treated thousands of patients around the world.

Looking forward, electron IORT potentially has a role in the treatment for what are often classified as locally advanced or unresectable tumors. With improvements in neoadjuvant therapies, recent data suggests that imaging may no longer predict resectability for many patients. Meanwhile, the proximity of sensitive organs often limits the total dose that may be delivered with conventional radiation therapy.

For patients that are surgical candidates, electron IORT increases the effectiveness of the surgical intervention by treating suspect surgical margins and gross residual tumor to increase local control. In fact, recent results of combining IORT with improved systemic treatment for locally advanced unresectable and borderline resectable pancreatic cancer are more than encouraging; and clinical trials such as PACER are expanding the clinical knowledge of this potential.

IORT with electrons makes surgery possible for more patients. Simply stated, Mobetron is delivering a new future of care. Today.

The use of Electron IORT is supported by professional consensus guidelines from the National Comprehensive Cancer Network (NCCN), American Society for Radiation Oncology (ASTRO), the American Society of Breast Surgeons (ASBrS) as well as the American Brachytherapy Society (ABS). IORT, in specified patient groups, is not experimental. It's a viable treatment.

Electrons Make The Difference

Electron IORT is the only single treatment APBI technique identified by the ASTRO consensus guidelines. The ASTRO consensus guidelines recognize the use of single fraction electron-beam IORT modality for treating “suitable” patients with breast cancer. This further validates Mobetron and distinguishes it from all other IORT treatment options available in the fight against cancer.

PACER Trial Open to Further Study Effectiveness of IORT

PACER (Pancreatic AdenoCarcinoma with Electron intraoperative Radiation therapy) is a multi-institutional trial that will study the effectiveness of IORT during surgery after neoadjuvant therapy including FOLFIRNOX and chemoradiation in borderline resectable and locally advanced unresectable pancreatic cancer patients.

All for One.
One for All.

Of course, we would love to see a Mobetron in every cancer center and clinic. Because we believe electron IORT with Mobetron is designed to benefit so many.

At the same time, we understand the realities of cancer care in this era. It takes time for innovation to take hold. Hospital administrators are constantly balancing capital expenditures with budget. Leading radiation oncologists have their preferences of tools, whether it comes as a result of experience or training.

We only ask this one simple question: **If the benefits for the facility, the physician, and the patient are so clearly illustrated over two decades of clinical data, then why shouldn't Mobetron become a part of your comprehensive cancer program?**

Facility Benefits

- Return On Investment
- Enhanced Productivity
- Reduced Risk
- Broader Application
- Competitive Advantage
- Recruitment
- Effective Treatment
- Proven Data
- Unmatched Support

Physician Benefits

- Multiple Indications
- Portability
- Self-Shielded
- Efficient Workflow
- Greater Precision
- Adjustable Penetration
- Shorter Treatment Time
- Better Cosmesis
- Reduced Toxicity

Patient Benefits

- Improved Local Control
- Highly-Targeted Radiation
- Shorter Treatment Time
- Shorter Recovery Time
- Fewer Side Effects
- Greater Comfort
- Better Cosmetic Outcomes
- Treatment Option for Unresectable Tumors

Contact

+1 408.636.1020
sales@intraop.com

intraop.com

755-00048 REV. B

About IntraOp

IntraOp uses the power and precision of electron therapy to advance patient treatment. As the pioneer in portable electron-beam Intraoperative Radiation Therapy (IORT), our technology is proven effective in more than two decades of clinical data and over 20,000 patients treated worldwide. And we're always innovating: to improve the efficiency and effectiveness of patient treatments. Constantly driving to advance the standard of care: to equip the world's leading physicians and centers by empowering them to offer better treatment to their patients. At IntraOp, we are accelerating the cure.

INTERESTED IN THE FUTURE OF IORT?

Learn more about how Mobetron can impact your facility's bottom line.

Learn more at intraop.com